UCHL1 and cancer: The list of top ranked candidate compounds included the DNA-damaging agent oxaliplatin and two PARP inhibitors (Niraparib and Olaparib), further supporting the assumption that genotoxic stress represents a vulnerability for UCHL1-related cancers and raising the attractive question of whether UCHL1-related cancers might benefit from combined radio-chemotherapy.